ARTHUR GROLLMAN, M.D., Ph.D., F.A.C.P.; ROBERT L. JOHNSON, M.D.; WILLIAM W. REGAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
Although patients with Hodgkin's disease may in many cases be controlled satisfactorily for a number of years by the use of irradiation, nitrogen mustard and triethylene melamine, a state of refractoriness to these agents ultimately ensues. The addition to our therapeutic armamentarium of other agents for the palliative control of this fatal disorder is obviously desirable.
The recognition of the radiomimetic potentialities of colchicine led early to its trial in the control of neoplastic processes.1 However, the toxicity as well as the ineffectiveness of this drug in the conditions in which it was first tried discouraged its further use, although
GROLLMAN A, JOHNSON RL, REGAN WW. A CLINICAL EVALUATION OF COLCHICINE IN THE TREATMENT OF HODGKIN'S DISEASE*. Ann Intern Med. 1955;42:154–170. doi: https://doi.org/10.7326/0003-4819-42-1-154
Download citation file:
Published: Ann Intern Med. 1955;42(1):154-170.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use